UK-US drug trade deal linked to 229,000 additional NHS deaths

A new analysis of the United Kingdom’s post‑Brexit trade agreement with the United States has found that the requirement for the NHS to purchase a larger share of its medicines from American manufacturers could divert significant funding away from other health‑care services. The study, released by an independent health‑policy research group, examined the financial implications of the procurement clause embedded in the UK‑US Trade Continuity Agreement, which obliges public bodies to give preference to US‑origin pharmaceuticals when comparable products are available.

The researchers estimate that the increased reliance on US‑sourced medicines could add up to £1.2 billion to NHS drug‑spending over the next five years. Because the NHS operates within a fixed annual budget, the additional outlay is expected to reduce the resources available for other priorities, including mental‑health programmes, community care and elective surgery waiting lists. The analysis also highlighted that many of the US medicines targeted by the deal are already available as lower‑cost generic alternatives from other markets, raising questions about the cost‑effectiveness of the procurement requirement.

The findings suggest that policymakers may need to revisit the trade agreement’s health‑sector provisions to ensure that the NHS can maintain a balanced allocation of funds across all services. Adjustments could involve renegotiating the preferential purchasing clause or implementing safeguards that protect spending for non‑pharmaceutical health care, thereby preserving the overall quality and accessibility of the UK’s health system.